Not for human consumption

Cagrilintide Peptide: Long-Acting Amylin Analog (NNC0174-0833) | Research Grade

Cagrilintide research peptide: ≥99% HPLC-verified purity, manufactured in LiveWell’s own Dallas cGMP facility. Cagrilintide (NNC0174-0833, AM833) is a 37-amino-acid lipidated amylin analog developed by Novo Nordisk, the amylin half of CagriSema and the compound behind the REDEFINE Phase 3 program published in the New England Journal of Medicine. Supplied as a 10 mg lyophilized vial for in-vitro laboratory research use only.

Coming soon: pre-orders are open now. The first production batch is in the manufacturing and QC queue. Expected ship date: to be announced. Pre-orders ship in the order received once the batch clears third-party testing and the COA is published. Your card is charged at checkout and you can cancel any time before shipment for a full refund.

CAS Number: 1415456-99-3 · Development codes: NNC0174-0833, AM833
Vial size: 10 mg lyophilized powder
Class: Dual amylin and calcitonin receptor agonist, once-weekly exposure profile in published trials
Purity: ≥99% HPLC, third-party tested, COA published on release
Shipping: USA same-day once released (orders before 2pm CT, Mon to Fri) · free over $200

Related: Eloralintide · Semaglutide · Retatrutide

For laboratory research use only. Not for human or animal consumption. Full details ↓

$ 119.99

Available on backorder

⚠️ Strictly for laboratory research use only. Not for human or animal consumption.

Quantity	Price	Discount
3-5	$ 107.99	10%
6-9	$ 101.99	15%
10+	$ 95.99	20%

Available on backorder

Add $ 200.00 to cart and get free shipping!

Description

Cagrilintide: Long-Acting Amylin Analog for Research Use

Cagrilintide (NNC0174-0833) is a syntBuy Cagrilintide 10mg | Amylin Analog Peptide | LiveWellhetic, long-acting amylin analog engineered from the structure of human amylin with a C20 fatty diacid attached at the N-terminus for albumin binding. Amylin is the 37-amino-acid hormone co-secreted with insulin by pancreatic beta cells; in published physiology it slows gastric emptying, suppresses glucagon and signals satiation through hindbrain circuits. Cagrilintide is the most-studied of the second-generation amylin analogs: it has a completed Phase 2 monotherapy trial in The Lancet, a Phase 3 program (REDEFINE) in combination with semaglutide published in the New England Journal of Medicine, and a dedicated moCagrilintide (NNC0174-0833) 10mg research peptide, the long-acting amylin analog behind CagriSema. cGMP made in Dallas, COA included. Pre-order today.notherapy Phase 3 program (RENEW). LiveWell supplies it as a 10 mg lyophilized vial strictly for in-vitro laboratory research use only.

Chemical Information

Name: Cagrilintide (NNC0174-0833, AM833)
CAS Number: 1415456-99-3
Type: Synthetic lipidated amylin analog (research grade)
Length: 37 amino acids, Cys3 to Cys8 disulfide, C20 diacid via gamma-glutamate linker
Molecular weight: approximately 4409 g/mol
Receptor profile: Dual amylin and calcitonin receptor agonist
Exposure profile: half-life of roughly 159 to 195 hours reported in Phase 1b, supporting once-weekly dosing in trials
Vial size: 10 mg lyophilized powder
Purity: ≥99% (HPLC, third-party tested)

Why Researchers Study Cagrilintide

1. Amylin pathway reference compound. Cagrilintide is the benchmark long-acting amylin analog against which newer selective agonists such as Eloralintide are compared. Its dual amylin and calcitonin receptor activity makes it the natural comparator in receptor-selectivity research.

2. Combination research with incretin agonists. The CagriSema program pairs cagrilintide with semaglutide; the published Phase 1b and Phase 3 data are the largest body of evidence for combining an amylin signal with a GLP-1 signal, which is why it is studied next to Semaglutide and Tirzepatide.

3. Structure and half-life. The J Med Chem discovery paper documents how lipidation and sequence changes turned a peptide with a minutes-long half-life into a weekly-exposure molecule, a template used across the class.

4. Glycemic and metabolic endpoints. REDEFINE 2 and the REIMAGINE studies report HbA1c outcomes in type 2 diabetes cohorts, extending the research questions beyond body weight.

Published Clinical Literature (Research Reference)

For context only. These are results from Novo Nordisk’s investigational drug program. These are results cited from peer-reviewed sources; they are not claims about LiveWell’s research-grade material.

Phase 1b with semaglutide (The Lancet, 2021): 96 participants, 20 weeks; body-weight change of minus 15.7% to minus 17.1% with cagrilintide plus semaglutide versus minus 9.8% with semaglutide plus placebo; half-life 159 to 195 hours.
Phase 2 monotherapy (The Lancet, 2021): 706 participants, 26 weeks; minus 6.0% to minus 10.8% across 0.3 to 4.5 mg versus minus 3.0% placebo; the 4.5 mg group exceeded liraglutide 3.0 mg; GI adverse events 41% to 63% versus 32%.
REDEFINE 1, Phase 3 CagriSema (NEJM, 2025): 3,417 participants, 68 weeks; minus 20.4% with CagriSema versus minus 3.0% placebo; cagrilintide alone minus 11.8% (sponsor estimand).
REDEFINE 2, type 2 diabetes (NEJM, 2025): 1,206 participants, 68 weeks; minus 13.7% versus minus 3.4%; HbA1c 6.5% or lower reached by 73.5% versus 15.9%.
Regulatory: CagriSema NDA filed with the FDA in December 2025, decision expected late 2026; monotherapy Phase 3 (RENEW) began Q4 2025. Not approved anywhere as of September 2026.

Storage & Handling

Store lyophilized vials refrigerated at 2 to 8°C, protected from light and heat
Reconstitute with bacteriostatic water; reconstituted material has a shorter storage window
Follow your laboratory’s standard peptide handling protocol

⚠️ Disclaimer: Cagrilintide research peptide is intended strictly for laboratory research and in-vitro use only. It is not a drug, food, cosmetic, or dietary supplement. This product has not been evaluated or approved by the FDA and is not for human or veterinary use. No therapeutic, weight-management or metabolic-health claims are made or implied.

Regulatory status: Cagrilintide is an investigational compound in clinical development by Novo Nordisk and is not approved for any use in any country as of September 2026. The research-grade material sold by LiveWell is not a drug product: it is not manufactured, compounded, or approved for pharmaceutical use, and is strictly for in-vitro laboratory research. Nothing on this page constitutes medical advice.

Cagrilintide research reference: View the Phase 2 monotherapy trial on PubMed

Pre-Order Cagrilintide Research Peptide: cGMP Manufactured in Dallas, TX

Qualified researchers can pre-order Cagrilintide directly from the manufacturer. LiveWell Peptides produces research-grade Cagrilintide in our cGMP facility in Dallas, Texas. Every vial is third-party tested to verify ≥99% HPLC purity, amino acid identity by mass spectrometry, and endotoxin limits by LAL testing, and the batch COA is published on our COA page on the day of release. Pre-orders ship in the order received (expected ship date: to be announced); once released, US orders placed before 2pm CT (Mon to Fri) ship same-day in cold-chain packaging, with free domestic shipping over $200. International shipping is available.

Why Researchers Source Cagrilintide from LiveWell

Documentation, not claims. Every batch ships with a verified COA confirming identity and purity, published on our COA page rather than supplied only on request.

Four-point analytical testing. HPLC for purity, mass spectrometry for amino acid identity, and LAL testing for endotoxins, with independent third-party verification on top of in-house quality control.

US manufacturing and cold-chain logistics. Orders ship from our Dallas, Texas facility, with international shipping to Colombia, Mexico, Brazil, Argentina, Chile and Peru.

Related research compounds

Eloralintide (Selective amylin agonist) · Semaglutide (GLP-1) · Tirzepatide (Dual GIP/GLP-1) · Retatrutide (Triple agonist) · Bacteriostatic Water · Certificates of Analysis

Research literature

Selected peer-reviewed sources for research reference:

Kruse T et al. (2021). Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. PMID: 34288673
Enebo LB et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg: a phase 1b trial. Lancet. PMID: 33894838
Lau DCW et al. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a phase 2 trial. Lancet. PMID: 34798060
Garvey WT et al. (2025). Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med. PMID: 40544433
Davies MJ et al. (2025). Cagrilintide and semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2). N Engl J Med. PMID: 40544432

References are provided for research reference only. Inclusion of literature does not constitute a recommendation, endorsement, or claim for any specific use of LiveWell Peptides products. Products are sold for laboratory and research use only and are not intended for human consumption, injection, topical application, or any other administration to the human body.

Frequently Asked Questions

What is Cagrilintide?

Cagrilintide (NNC0174-0833, CAS 1415456-99-3) is a 37-amino-acid lipidated amylin analog developed by Novo Nordisk that activates both amylin and calcitonin receptors. We supply it as a 10 mg lyophilized vial strictly for in-vitro laboratory research.

How does Cagrilintide differ from Eloralintide?

Both are long-acting amylin analogs. Cagrilintide is a dual amylin and calcitonin receptor agonist, while Eloralintide is described in its discovery paper as selective for the AMY1 receptor. Receptor selectivity is the main distinction discussed in the literature, including the tolerability comparisons in rats.

Is Cagrilintide a GLP-1 peptide?

No. Cagrilintide is an amylin analog, not a GLP-1 receptor agonist. It is the amylin half of CagriSema, where it is coformulated with semaglutide, which is why it is studied alongside Semaglutide and Tirzepatide.

What is CagriSema?

CagriSema is the fixed-dose combination of cagrilintide and semaglutide. In REDEFINE 1 (NEJM, 2025, 3,417 participants, 68 weeks) it reported minus 20.4% body-weight change versus minus 3.0% for placebo. These are published clinical findings cited for research reference only.

What did the Phase 2 monotherapy trial report?

The 26-week Phase 2 trial in The Lancet (706 participants) reported minus 6.0% to minus 10.8% body-weight change across 0.3 to 4.5 mg once weekly versus minus 3.0% for placebo, with gastrointestinal events the most common adverse events. Cited for research reference only.

What purity is LiveWell Cagrilintide, and is a COA included?

Every batch is third-party tested at ≥99% purity by HPLC, with mass spectrometry identity confirmation and LAL endotoxin testing. The batch Certificate of Analysis is published on our COA page the day the pre-order batch is released.

How should Cagrilintide be stored and reconstituted?

Store the lyophilized vial refrigerated at 2 to 8°C, protected from light and heat. Reconstitute with bacteriostatic water; reconstituted material has a considerably shorter storage window.

How do pre-orders work, and when will it ship?

Pre-orders are charged at checkout and ship in the order received once the first batch clears third-party testing and the COA is published. You will receive tracking the day it ships. If you change your mind before shipment, contact us for a full refund.

Is Cagrilintide a drug or supplement?

No. Cagrilintide is an investigational compound that has not been approved by the FDA or any regulator. The research-grade material sold by LiveWell is not a drug product, dietary supplement, food or cosmetic, and it is not intended for human or animal consumption.

Péptidos de investigación disponibles con envío internacional. Cagrilintida de grado de investigación fabricada en instalaciones cGMP en Dallas, Texas. Certificado de análisis incluido con cada lote. Solo para uso en investigación.

Research Use Only Disclaimer: This product is sold strictly for in vitro laboratory research. NOT for human or animal consumption. LiveWell Peptides makes no medical claims.